PVLAPALVELLA THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$39M
- 174% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired17% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $28M | $25M | $39M | — | — | |
| Operating income | −$52M | −$43M | −$12M | −$14M | −$39M | 174% |
| Net income | −$46M | −$33M | $19M | −$17M | −$42M | 139% |
| Operating cash flow | −$8M | −$60M | −$14M | −$11M | −$25M | 131% |
| Capex | $949K | $1M | $171K | — | — | |
| Stock-based comp | $5M | $4M | $603K | $830K | $6M | 671% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $9M · 33
- Net
- −$9M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 126 | — |
| FY2024 | — | — | 14 | — |
| FY2023 | — | — | 18 | — |